Vcanbio Cell & Gene Engineering Corp., Ltd

Shanghai Stock Exchange 600645.SS

Vcanbio Cell & Gene Engineering Corp., Ltd Total Non-Current Liabilities for the year ending December 31, 2023: USD 18.45 M

Vcanbio Cell & Gene Engineering Corp., Ltd Total Non-Current Liabilities is USD 18.45 M for the year ending December 31, 2023, a -20.15% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • Vcanbio Cell & Gene Engineering Corp., Ltd Total Non-Current Liabilities for the year ending December 31, 2022 was USD 23.11 M, a 39.88% change year over year.
  • Vcanbio Cell & Gene Engineering Corp., Ltd Total Non-Current Liabilities for the year ending December 31, 2021 was USD 16.52 M, a 39.73% change year over year.
  • Vcanbio Cell & Gene Engineering Corp., Ltd Total Non-Current Liabilities for the year ending December 31, 2020 was USD 11.82 M, a 5.81% change year over year.
  • Vcanbio Cell & Gene Engineering Corp., Ltd Total Non-Current Liabilities for the year ending December 31, 2019 was USD 11.17 M, a -59.87% change year over year.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
Loading...
SV Wall Street
Shanghai Stock Exchange: 600645.SS

Vcanbio Cell & Gene Engineering Corp., Ltd

CEO Mr. Hongqi Wang
IPO Date May 4, 1993
Location China
Headquarters Huayuan Industrial Park
Employees 2,209
Sector Health Care
Industries
Description

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the preparation and storage of cell tests in the People's Republic of China. The company provides cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totipotent stem cells, immune cells, adipose stem cells, and dental stem cells. It also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, safe medication guide gene testing for children and adults, disease genetic testing, disease susceptibility gene testing, etc.; and in vitro diagnostic raw materials, such as monoclonal antibodies and polyclonal antibody products. In addition, the company is involved in the research, development, production, and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and experimental synthetic agents; and in vitro diagnostic reagents and medical devices. Vcanbio Cell & Gene Engineering Corp., Ltd was founded in 1992 and is based in Tianjin, the People's Republic of China.

Similar companies

600664.SS

Harbin Pharmaceutical Group Co., Ltd.

USD 0.51

NA

600633.SS

Zhejiang Daily Digital Culture Group Co.,Ltd.

USD 1.41

NA

600666.SS

Aurora Optoelectronics Co.,Ltd.

USD 0.30

NA

600618.SS

Shanghai Chlor-Alkali Chemical Co., Ltd.

USD 1.56

NA

600636.SS

China Reform Culture Holdings Co., Ltd.

USD 1.02

NA

StockViz Staff

February 2, 2025

Any question? Send us an email